Janssen secures FDA approval for Akeega to treat BRCA-positive mCRPC
The FDA approval is based on the Phase 3 MAGNITUDE study, in which Akeega plus prednisone significantly improved…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Aug 23
The FDA approval is based on the Phase 3 MAGNITUDE study, in which Akeega plus prednisone significantly improved…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Aug 23
Inversago’s lead asset, INV-202, specifically blocks the receptor protein CB1, which plays key role in metabolism and appetite…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Aug 23
The patent provides protection of the enema formulation of cobitolimod, that is currently under evaluation in the ongoing…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
27 Jul 23
Under the expanded partnership, Calibr will present to AbbVie, several discovery targets and preclinical assets of mutual interest…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Jul 23
DTx Pharma is engaged in developing small interfering RNA (siRNA) therapeutics for neuroscience indications, leveraging its FALCON platform,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 Jul 23
Versanis’ lead asset, bimagrumab is a monoclonal antibody, currently being developed in the BELIEVE Phase 2b study, as…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 Jul 23
Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Jul 23
ZyVersa’s Cholesterol Efflux Mediator VAR 200 is currently in Phase 2a development to reduce renal cholesterol and lipid…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Jul 23
Biocon Biologics has transitioned a portfolio of biosimilars including bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Jul 23
Cyltezo is the only adalimumab biosimilar with Phase III comparative clinical studies in rheumatoid arthritis, plaque psoriasis and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates